RxDoctor Payments Data

Maria Gigante-Baggett

Adult Health · East Syracuse, NYNPI 1356488399

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $86,850 of the $92,146 with a category attached, or 94.3%. Organon accounts for 86.9% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $47,033 and has fallen 96.5% since, to $1,658 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$92,146in general payments, 2019–2025

Across 385 payments — averaging $239.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$80K
  • Merck$8K
  • AbbVie$626
  • Mayne Pharma Commercial LLC$554
  • Novo Nordisk$540
  • Pfizer$377
  • plus $2K from 27 others

What the payments were for

  • Speaking & faculty fees$86,85094%
  • Travel & lodging$8551%
  • Food & beverage$4,3115%
  • Education$1300%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,146 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$3,288
Medicare patients
33
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated17$9,084
Estradiol60$8,278
EstringEstradiol11$5,282
VagifemEstradiol13$2,127
Estradiol (Twice Weekly)Estradiol13$784
ProgesteroneProgesterone, Micronized12$509
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$377$14,36728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →